Login to Your Account

‘Jazz’ age continues as Aerial deal adds to sleep drug portfolio

By Jennifer Boggs
Managing Editor

Monday, January 13, 2014

SAN FRANCISCO – Amid the flurry of deals and financings news to hit on the first day of the J.P. Morgan Healthcare Conference, Jazz Pharmaceuticals plc disclosed the latest acquisition to its growing pipeline, with the licensing of a Phase III-ready narcolepsy drug, and its goal of topping the $1 billion revenue mark in 2014.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription